10-K: TransCode Therapeutics Finalizes Key Licensing and Financing Deals

TransCode Therapeutics, Inc. has entered into a significant equity issuance and registration rights agreement with Unleash Immuno Oncolytics, Inc., alongside a standby equity purchase agreement with YA II PN, LTD, bolstering its financial and strategic position.

Summary

• TransCode Therapeutics, Inc. has entered into an Equity Issuance and Registration Rights Agreement with Unleash Immuno Oncolytics, Inc., dated March 2, 2026.
• This agreement is in connection with an Exclusive License Agreement between the two companies, also dated March 2, 2026.
• Unleash Immuno Oncolytics, Inc. will hold 181,818 shares of Preferred Stock Payment Shares as collateral for indemnification obligations.
• TransCode Therapeutics also entered into a Standby Equity Purchase Agreement (SEPA) with YA II PN, LTD, allowing for the sale of up to $14 million of common stock.
• Additionally, TransCode will issue convertible promissory notes to YA II PN, LTD, totaling up to $6 million, with the first note of $1 million expected shortly after the filing of the Form 10-K.
• The company also amended its license agreement with Massachusetts General Hospital (MGH) on August 15, 2025, updating diligence requirements and milestone payments.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to significant operating losses, a precarious cash position, and identified material weaknesses in internal controls, despite positive developments in licensing and clinical trial completion.

Positives

• Secured a strategic licensing agreement with Unleash Immuno Oncolytics, Inc., expanding its pipeline with an oncolytic immunotherapy platform.
• Established a flexible financing facility with YA II PN, LTD, providing potential access to up to $20 million in capital through a SEPA and convertible notes.
• Received a $1.01 million NIH grant in September 2024 to support IND-enabling and clinical trial activities for TTX-MC138.
• Completed the Phase 1a clinical trial for TTX-MC138, meeting the primary endpoint of safety and demonstrating positive pharmacodynamic effects.
• Received a $75,000 license amendment fee from MGH, indicating continued progress in their collaboration.
• Maintained Nasdaq listing compliance as of June 2, 2025.

Negatives

• The company has identified material weaknesses in its internal control over financial reporting, which are still being remediated.
• TransCode Therapeutics has incurred significant operating losses since inception, with a net loss of $34.7 million for the year ended December 31, 2025.
• The company has an accumulated deficit of approximately $97.9 million as of December 31, 2025.
• The company's cash position of $17.8 million at December 31, 2025, is projected to fund operations only through approximately year-end 2026, indicating a need for further capital.
• The company's ability to continue as a going concern raises substantial doubt, as noted by its independent registered public accounting firm.
• The company has undertaken multiple reverse stock splits, indicating potential challenges in maintaining share price compliance with listing requirements.

Risks

• The company's ability to continue as a going concern is subject to substantial doubt due to recurring losses and negative cash flows.
• Failure to obtain stockholder approval for the conversion of Series A and Series C Preferred Stock could delay or prevent the conversion into common stock.
• The company faces substantial competition from larger pharmaceutical and biotechnology companies with greater financial resources.
• Clinical trials are expensive, lengthy, and have uncertain outcomes; failure at any stage could materially harm the business.
• The company relies heavily on third-party manufacturers and CROs, creating risks of supply interruption, quality issues, or contractual failures.
• Intellectual property protection is critical, and the company may face challenges in obtaining, maintaining, and enforcing patents.
• Cybersecurity threats pose a risk to the company's operations and data security.
• The company's limited operating history and early-stage development of most therapeutic candidates make future success difficult to predict.
• The company may not be able to secure additional funding on commercially acceptable terms, potentially forcing delays or discontinuation of development programs.

Future Outlook

The company anticipates increased expenses due to ongoing R&D, clinical trials, and operational scaling. It expects to require substantial additional capital through equity or debt financings to fund operations and development plans beyond approximately year-end 2026, as current cash reserves are projected to be insufficient.

Management Comments

• We believe that our TTX platform can be effective in developing treatments for cancer and pathologies related to macrophage dysfunction.
• We believe that demonstrating our ability to overcome the challenge of RNA delivery to genetic targets outside of the liver, and specifically to tumors and metastases, would represent a major step forward in unlocking therapeutic access to genetic targets involved in a range of cancers.
• We believe that results from the Phase 1a trial support advancement to a Phase 2a clinical trial with the treatment dose selected based on the Phase 1a results.

Industry Context

StockSavvy.ai notes that TransCode Therapeutics is operating in the highly competitive and rapidly evolving biopharmaceutical sector, specifically focusing on immuno-oncology and RNA therapeutics. The company's strategy of leveraging its proprietary TTX drug design engine for targeted delivery of RNA therapeutics addresses a key industry challenge. The recent licensing agreement with Unleash Immuno Oncolytics and the acquisition of Polynoma indicate a strategic effort to broaden its pipeline and therapeutic modalities, positioning it against competitors in the oncology space.

Comparison to Industry Standards

• The company's lead candidate, TTX-MC138, targets microRNA-10b, a master regulator of metastatic cell viability, a mechanism that is gaining traction in oncology research.
• The TTX platform's design aims to overcome delivery challenges faced by other RNA therapeutics, differentiating it from lipid and liposomal nanoparticle platforms that primarily target the liver.
• Seviprotimut-L, acquired through the Polynoma acquisition, is a polyvalent vaccine for melanoma adjuvant treatment, a field where immune checkpoint inhibitors like Keytruda and Opdivo are established standards of care.
• The Unleash program includes oncolytic adenoviruses engineered to deliver multi-cytokine payloads, a next-generation approach in immunotherapy, building on the success of earlier oncolytic adenoviruses like CG0070.

Legal Proceedings

• The company is rigorously disputing claims by an investment bank regarding entitlement to fees.

Related Party Transactions

• The company acquired ABCJ, LLC from DEFJ, LLC, issuing common stock and Series A Preferred Stock to DEFJ.
• The company entered into an Investment Agreement with DEFJ to purchase Series B Preferred Stock for approximately $25 million, consisting of a cash subscription and a promissory note.
• The company entered into a Repurchase Agreement with DEFJ, granting DEFJ the right to repurchase ABCJ membership interests under certain conditions.
• The company entered into a Contingent Value Rights Agreement with Vstock Transfer, LLC, related to the acquisition, entitling holders to 50% of net proceeds from certain payments.

Stakeholder Impact

• Shareholders may experience dilution due to potential future equity issuances and the conversion of preferred stock.
• The company's going concern status and need for additional capital could negatively impact investor confidence and stock value.
• The company's ability to secure regulatory approvals and achieve commercial success for its therapeutic candidates will impact patients' access to potential new treatments.
• Creditors and suppliers may face risks if the company cannot meet its financial obligations due to its cash position and operating losses.

Next Steps

• Advance TTX-MC138 in a planned Phase 2a clinical trial.
• Conduct preclinical research combining seviprotimut-L and TTX-MC138 to explore potential synergies.
• Seek stockholder approval for the conversion of Series A and Series C Preferred Stock.
• Continue remediation efforts for material weaknesses in internal control over financial reporting.
• Manage cash reserves and pursue additional capital raises to fund operations beyond year-end 2026.

Key Dates

Recommendation

While TransCode Therapeutics has made progress with its lead candidate's Phase 1a trial completion and secured new licensing and financing agreements, the company's significant operating losses, accumulated deficit, and the identified material weaknesses in internal controls, coupled with a precarious cash runway, present substantial risks. The need for further capital raises and the uncertainty surrounding stockholder approval for preferred stock conversions warrant a cautious approach. Therefore, a 'hold' recommendation is appropriate, pending clearer signs of financial stability and successful progression through later-stage clinical development.

Keywords

TransCode Therapeutics, Equity Issuance, Registration Rights, Unleash Immuno Oncolytics, Licensing Agreement, Standby Equity Purchase Agreement, YA II PN, LTD, Convertible Notes, Financing, TTX-MC138, Clinical Trials, Oncology, Biotechnology, SEC Filing, Form 10-K